Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
Kana Watanabe(Miyagi Prefectural Hospital Organization), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Hiromi Nagashima(Iwate Medical University), Ryota Saito(Tohoku University), Hiroshi Terasaki, Atsushi Nakamura(Sendai Kousei Hospital), Nobuyuki Tanaka(Waseda University), Shunichi Sugawara(Sendai Kousei Hospital), Eisaku Miyauchi(Tohoku University)
Cited by 9
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695